Notify me when Bain Capital Life Sciences Investors, LLC files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 19 | $1,305,660,830 | +$77,111,557 | -$495,674,870 | -$418,563,313 | HTFL, NAMS, OLMA, SVRA, PHVS | 13F-HR | 17 Feb 2026, 16:30 |
| Q3 2025 | 21 | $1,506,676,328 | +$477,923,806 | -$195,054,653 | +$282,869,153 | HTFL, NAMS, CDTX, PHVS, OLMA | 13F-HR | 14 Nov 2025, 16:30 |
| Q2 2025 | 23 | $799,265,446 | +$100,728,600 | -$29,971,169 | +$70,757,431 | NAMS, CDTX, NUVL, PHVS, DNTH | 13F-HR | 14 Aug 2025, 16:00 |
| Q1 2025 | 24 | $675,912,941 | +$22,752,626 | -$5,019,095 | +$17,733,531 | NAMS, NUVL, PHVS, IRON, DNTH | 13F-HR | 15 May 2025, 07:00 |
| Q4 2024 | 26 | $850,096,624 | +$87,588,005 | -$173,227,071 | -$85,639,066 | NAMS, NUVL, PHVS, IRON, DNTH | 13F-HR | 14 Feb 2025, 08:19 |
| Q3 2024 | 24 | $961,175,669 | +$14,170,320 | -$12,076,582 | +$2,093,738 | NUVL, NAMS, IRON, DNTH, SVRA | 13F-HR | 14 Nov 2024, 07:01 |
| Q2 2024 | 25 | $910,841,673 | +$39,646,239 | -$81,959,812 | -$42,313,573 | NUVL, NAMS, IRON, DNTH, PHVS | 13F-HR | 12 Aug 2024, 13:30 |
| Q1 2024 | 26 | $1,244,287,799 | +$186,651,514 | -$209,789,510 | -$23,137,996 | NAMS, NUVL, DNTH, IRON, KYTX | 13F-HR | 15 May 2024, 13:00 |
| Q4 2023 | 27 | $1,043,257,107 | +$123,502,891 | -$202,379,394 | -$78,876,503 | NUVL, NAMS, PHVS, IRON, MDGL | 13F-HR | 13 Feb 2024, 16:30 |
| Q3 2023 | 31 | $894,220,736 | +$20,798,408 | -$82,802,945 | -$62,004,537 | NUVL, PHVS, NAMS, SWTX, IRON | 13F-HR | 14 Nov 2023, 16:00 |
| Q2 2023 | 32 | $970,993,637 | +$87,387,479 | -$74,618,279 | +$12,769,200 | NUVL, NAMS, SWTX, PHVS, IRON | 13F-HR | 14 Aug 2023, 16:31 |
| Q1 2023 | 34 | $800,117,000 | +$95,380,972 | -$125,379,020 | -$29,998,048 | NAMS, NUVL, SWTX, IRON, NTRA | 13F-HR | 15 May 2023, 16:12 |
| Q4 2022 | 33 | $894,849,000 | +$210,040,116 | -$66,150,258 | +$143,889,858 | SWTX, NUVL, NAMS, NTRA, MRSN | 13F-HR | 14 Feb 2023, 07:27 |
| Q3 2022 | 33 | $837,757,000 | +$58,376,805 | -$84,936,543 | -$26,559,738 | SWTX, NUVL, MRSN, ARQT, DVAX | 13F-HR | 14 Nov 2022, 16:00 |
| Q2 2022 | 35 | $852,695,000 | +$73,638,521 | -$43,304,799 | +$30,333,722 | SWTX, DVAX, PHVS, ARQT, EQRX | 13F-HR | 15 Aug 2022, 16:02 |
| Q1 2022 | 34 | $1,029,621,000 | +$61,157,380 | -$5,376,000 | +$55,781,380 | SWTX, DVAX, ARQT, PHVS, RPID | 13F-HR | 16 May 2022, 16:01 |
| Q4 2021 | 34 | $1,260,974,000 | +$141,483,591 | -$79,435,584 | +$62,048,007 | SWTX, DVAX, RPID, ARQT, EQRX | 13F-HR | 14 Feb 2022, 08:31 |
| Q3 2021 | 33 | $1,604,767,000 | +$369,111,121 | -$228,836,281 | +$140,274,840 | SWTX, DVAX, RPID, AVIR, IVVD | 13F-HR | 15 Nov 2021, 16:08 |
| Q2 2021 | 30 | $1,526,199,000 | +$50,103,734 | -$57,036,000 | -$6,932,266 | SWTX, AVIR, DVAX, DRNA, ARQT | 13F-HR | 16 Aug 2021, 16:23 |
| Q1 2021 | 31 | $1,765,308,000 | +$282,434,911 | -$172,621,436 | +$109,813,475 | SWTX, AVIR, ARQT, DVAX, ANNX | 13F-HR | 17 May 2021, 06:58 |
| Q4 2020 | 26 | $1,592,801,000 | +$450,466,989 | -$168,962,931 | +$281,504,058 | SWTX, AVIR, ARQT, MRSN, ANNX | 13F-HR | 16 Feb 2021, 06:13 |
| Q3 2020 | 22 | $1,049,955,000 | +$201,778,000 | -$56,092,000 | +$145,686,000 | SWTX, ARQT, ANNX, DRNA, MRSN | 13F-HR | 16 Nov 2020, 08:10 |
| Q2 2020 | 15 | $931,798,000 | +$164,332,233 | -$41,508,985 | +$122,823,248 | SWTX, ARQT, DRNA, DVAX, MRSN | 13F-HR | 14 Aug 2020, 08:05 |
| Q1 2020 | 11 | $568,320,000 | +$126,765,874 | -$19,486,624 | +$107,279,250 | SWTX, ARQT, DRNA, CNST, DVAX | 13F-HR | 15 May 2020, 08:00 |
| Q4 2019 | 10 | $670,536,000 | +$175,574,953 | -$71,597,802 | +$103,977,151 | SWTX, CNST, DRNA, DVAX, REPL | 13F-HR | 14 Feb 2020, 08:08 |
| Q3 2019 | 7 | $388,402,000 | +$207,575,065 | $0 | +$207,575,065 | SWTX, DRNA, SLDB, REPL, DVAX | 13F-HR | 14 Nov 2019, 08:32 |
| Q2 2019 | 5 | $196,868,000 | $0 | -$52,887,949 | -$52,887,949 | DRNA, REPL, MRNS, SLDB, APTX | 13F-HR | 14 Aug 2019, 09:01 |
| Q1 2019 | 6 | $250,119,000 | $0 | -$39,008,083 | -$39,008,083 | DRNA, REPL, IFRX, MRNS, SLDB | 13F-HR | 15 May 2019, 09:01 |
| Q4 2018 | 6 | $292,636,000 | +$3,057,433 | $0 | +$3,057,433 | DRNA, IFRX, SLDB, APTX, REPL | 13F-HR | 14 Feb 2019, 08:30 |
| Q3 2018 | 6 | $440,629,000 | +$45,707,000 | $0 | +$45,707,000 | DRNA, SLDB, APTX, IFRX, REPL | 13F-HR | 14 Nov 2018, 06:42 |
| Q2 2018 | 5 | $0 | $0 | $0 | $0 | 13F-HR | 14 Aug 2018, 07:12 | |
| Q1 2018 | 4 | $169,604,000 | +$14,921,000 | $0 | +$14,921,000 | DRNA, IFRX, MRNS, SLDB | 13F-HR | 15 May 2018, 07:28 |
| Q4 2017 | 3 | $152,407,000 | $0 | $0 | $0 | DRNA, IFRX, MRNS | 13F-HR | 14 Feb 2018, 07:21 |